SOBER: Impact of Sourdough Bread Consumption on Long-term Energy Intake: A Pilot Study of Feasibility

Sponsor
KU Leuven (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05590611
Collaborator
(none)
100
1
2
22
4.5

Study Details

Study Description

Brief Summary

The present study is a pilot study examining whether long-term sourdough bread consumption reduces energy intake over a period of 4 weeks in free-living overweight participants.

Condition or Disease Intervention/Treatment Phase
  • Other: Dietary Intervention with Brown Bread
  • Other: Dietary Intervention with Sourdough Bread
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Impact of Sourdough Bread Consumption on Long-term Energy Intake: A Pilot Study of Feasibility (SOBER)
Anticipated Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Sep 1, 2024
Anticipated Study Completion Date :
Sep 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: Brown Bread

Other: Dietary Intervention with Brown Bread
The participants in this group will be asked to replace all their habitual bread intake by standard brown bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.

Active Comparator: Wholemeal Sourdough Bread

Other: Dietary Intervention with Sourdough Bread
The participants in thisgroup will be asked to replace all their habitual bread intake by wholemeal sourdough bread. The duration of the study for each participant is 4 weeks. Apart from the change in type of bread, participants will maintain their habitual diet.

Outcome Measures

Primary Outcome Measures

  1. Energy intake (kilocalories) [4 weeks]

    Assessed via 4-day food diaries using a mobile app

Secondary Outcome Measures

  1. Body weight [4 weeks]

  2. Blood lipid levels [4 weeks]

    Plasma total cholesterol, triglycerides, LDL and HDL cholesterol, colourimetrically

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Female and male participants

  • Age range 18 - 50

  • BMI range27 - 32 kg/m2 at screening visit

  • Regular eating pattern (3 meals per day on at least 5 days per week)

  • Habitual brown bread consumption of at least 1 slice per day (assessed by The European Prospective Investigation into Cancer (EPIC) Norfolk FFQ)

  • Stable body weight for the last 6 months

Exclusion Criteria:
  • Currently smoking or willingness to smoke during the study period

  • Pregnancy, lactation or wish to become pregnant during the study period

  • Previous or current gastrointestinal or endocrine disorders

  • Previous or current substance/alcohol dependence or abuse (> 2 units per day/14 units per week)

  • Coeliac disease or gluten sensitivity

  • Allergy/intolerance to milk, egg, nuts, soy or sesame

  • Habitual sourdough bread consumption of at least 1 slice per day (assessed by The European Prospective Investigation into Cancer (EPIC) Norfolk FFQ)

  • Excessive concern about eating habits or body weight as evidenced from scores < 18 on the restraint and disinhibition subscales of the Three-Factor Eating Questionnaire (Stunkard & Messick, 1985)

Contacts and Locations

Locations

Site City State Country Postal Code
1 KU Leuven Leuven Vlaams Brabant Belgium 3000

Sponsors and Collaborators

  • KU Leuven

Investigators

  • Principal Investigator: Kristin Verbeke, KU Leuven

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kristin Verbeke, Full professor, KU Leuven
ClinicalTrials.gov Identifier:
NCT05590611
Other Study ID Numbers:
  • S66499
First Posted:
Oct 21, 2022
Last Update Posted:
Oct 21, 2022
Last Verified:
Oct 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 21, 2022